Geode Capital Management’s Cognition Therapeutics CGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.05M Sell
910,006
-10,202
-1% -$12.1K ﹤0.01% 3348
2026
Q1
$699K Buy
920,208
+46,254
+5% +$53.8K ﹤0.01% 3470
2025
Q4
$1.18M Buy
873,954
+161,227
+23% +$262K ﹤0.01% 3324
2025
Q3
$963K Buy
712,727
+344,007
+93% +$469K ﹤0.01% 3389
2025
Q2
$114K Sell
368,720
-241
-0.1% -$81 ﹤0.01% 4029
2025
Q1
$155K Buy
368,961
+16,613
+5% +$9.76K ﹤0.01% 3916
2024
Q4
$247K Buy
352,348
+28,705
+9% +$14.2K ﹤0.01% 3831
2024
Q3
$152K Buy
323,643
+78,876
+32% +$81.3K ﹤0.01% 3986
2024
Q2
$406K Buy
244,767
+59,571
+32% +$119K ﹤0.01% 3646
2024
Q1
$337K Buy
185,196
+10,398
+6% +$21.5K ﹤0.01% 3758
2023
Q4
$323K Hold
174,798
﹤0.01% 3769
2023
Q3
$252K Sell
174,798
-1,700
-1% -$2.66K ﹤0.01% 3887
2023
Q2
$323K Buy
176,498
+53,900
+44% +$114K ﹤0.01% 3825
2023
Q1
$243K Hold
122,598
﹤0.01% 3948
2022
Q4
$257K Buy
122,598
+42,189
+52% +$85.2K ﹤0.01% 3958
2022
Q3
$152K Buy
80,409
+65,238
+430% +$136K ﹤0.01% 4356
2022
Q2
$32K Buy
15,171
+1,445
+11% +$3.73K ﹤0.01% 4859
2022
Q1
$37K Buy
+13,726
New +$52.9K ﹤0.01% 4861

Other funds holding CGTX

Geode Capital Management's CGTX Position: Q2 2026 in Review

Geode Capital Management reduced its Cognition Therapeutics (CGTX) stake by 1.1% in Q2 2026, selling an estimated $12.1K and leaving 910,006 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #3348.

Geode Capital Management first reported a position in CGTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.18M in Q4 2025. 64 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Geode Capital Management held 910,006 shares of Cognition Therapeutics worth $1.05M as of Q2 2026.
  • Geode Capital Management sold 10,202 Cognition Therapeutics shares in Q2 2026, an estimated $12.1K.
  • Cognition Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3348 holding.
  • Geode Capital Management first reported a position in Cognition Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Geode Capital Management's Cognition Therapeutics position peaked at $1.18M in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.